15 completed, 5 terminated, 2 withdrawn, 1 unknown. 23 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 15, Terminated 5, Withdrawn 2, Unknown 1 |
| Phase 1 | 11 | Completed 7, Terminated 2, Unknown 1, Withdrawn 1 |
Follow ProMune: new trials by email Literature Review of ProMune trials Research Report on ProMune
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria AMA1-C1/Alhydrogel® + CPG 7909 - Malaria | Phase 1 / Phase 2 | Completed | University of Oxford | 8 | 2010-01-01 | 2015-05-28 |
| Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells - Lymphoma, Mantle-Cell | Phase 2 | Completed | Ronald Levy | 59 | 2009-08-01 | 2020-01-13 |
| Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer Trastuzumab, PF03512676, Correlative Studies - Breast Cancer | Phase 2 | Terminated | Bhuvaneswari Ramaswamy | 6 | 2009-02-01 | 2016-01-14 |
| A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas PF-3512676, Local radiotherapy - Lymphoma, Non-Hodgkin, Lymphoma | Phase 2 | Completed | Ronald Levy | 30 | 2009-01-01 | 2017-03-14 |
| Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines - HIV Infections | Phase 1 / Phase 2 | Completed | University of Aarhus | 97 | 2008-01-01 | 2009-01-21 |
| A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. docetaxel, PF-3512676 - Breast Neoplasms | Phase 2 | Withdrawn | Pfizer | 2007-08-01 | 2015-05-04 | |
| PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer URLC10-177, TTK-567, CpG-7909 - Esophageal Cancer | Phase 1 / Phase 2 | Unknown | Wakayama Medical University | 29 | 2006-11-01 | 2010-09-09 |
| Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer pemetrexed, pemetrexed + PF-3512676 - Carcinoma, Non-Small Cell Lung | Phase 2 | Terminated | Pfizer | 36 | 2006-09-01 | 2009-09-28 |
| Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer PF-3512676 + Erlotinib, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Pfizer | 43 | 2006-08-01 | 2010-12-23 |
| Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + PF-3512676 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Terminated | Pfizer | 23 | 2005-12-01 | 2009-09-28 |
| Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. CPG 7909 - Mycosis Fungoides | Phase 1 / Phase 2 | Withdrawn | Stanford University | 2005-03-01 | 2016-12-01 | |
| Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma MAGE-3.A1 peptide and CpG 7909 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Ludwig Institute for Cancer Research | 1 | 2005-01-12 | 2022-10-07 |
| Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909 - Malignant Melanoma | Phase 1 / Phase 2 | Terminated | Ludwig Institute for Cancer Research | 23 | 2005-01-01 | 2022-10-10 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
| CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas CPG 7909 - Non-Hodgkin Lymphoma, Mycosis Fungoides | Phase 1 / Phase 2 | Completed | Ronald Levy | 30 | 2004-07-01 | 2014-08-01 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| CPG 7909 Injection in Melanoma CPG 7909 Injection, dacarbazine, Chemotherapy - Carcinoma, Melanoma | Phase 2 | Completed | Pfizer | 184 | 2003-12-01 | 2009-02-10 |
| CPG 7909 Injection in Non-Small Cell Lung Cancer CPG 7909, Chemotherapy - Carcinoma, Non-Small Cell Lung | Phase 2 | Completed | Pfizer | 116 | 2003-05-01 | 2009-02-10 |
| CPG 7909 in Patients With Cutaneous T-Cell Lymphoma PF-3512676 - Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Completed | Pfizer | 42 | 2003-01-01 | 2009-02-12 |
| CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer 0.04 mg/kg CpG 7909, Herceptin®, 0.08 mg/kg CpG 7909 - Carcinoma, Breast | Phase 2 | Completed | Pfizer | 16 | 2002-09-01 | 2009-03-12 |
Showing 20 of 23. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Melanoma (5) · Breast Neoplasms (4) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Carcinoma (2) · Carcinoma, Renal Cell (2) · Lymphoma, Mantle-Cell (2) · Mycosis Fungoides (2) · Breast Neoplasms, Male (1) · Esophageal Neoplasms (1) · HIV Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1)
Pfizer (11) · Ronald Levy (3) · Ludwig Institute for Cancer Research (2) · Bhuvaneswari Ramaswamy (1) · Mayo Clinic (1) · Stanford University (1) · University of Aarhus (1) · University of Oxford (1) · University of Southern California (1) · Wakayama Medical University (1)
United States (13) · Germany (3) · Belgium (2) · Canada (1) · Denmark (1) · Italy (1) · Japan (1) · United Kingdom (1)
Ronald Levy (3) · Adrian VS Hill, D.Phil, FRCP (1) · Bhuvaneswari Ramaswamy, MD (1) · Harold Burstein, M.D., Ph.D. (1) · Jeffrey Weber (1) · Lars Ostergaard, MD,PhD,DmSC (1) · Nicolas VanBaren, MD (1) · Nicolas van Baren, MD (1) · Ole Sogaard, MD (1) · Ronald Levy, MD (1) · Thierry Boon, PhD (1) · Thomas Witzig (1)
PMID 22045986, PMID 20504165, PMID 20697067, PMID 20874827, PMID 20888065, PMID 21799809, PMID 22854665, PMID 23792641, PMID 32558897, PMID 32632956
P30CA015083 (1)